Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20588789 | 0.78 | ATM (0.45) | TSHRNPSR1EDNRAALDH1A1EGFR | |
| SCHEMBL28787105 | 0.75 | MAPT (0.53) | TSHRNPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL7201340 | 0.73 | TSHR (0.51) | TSHRNPSR1ALDH1A1 | |
| SCHEMBL3732085 | 0.73 | TSHR (0.51) | TSHRNPSR1EDNRA | |
| SCHEMBL8343006 | 0.73 | TSHR (0.51) | TSHRNPSR1EDNRAEDNRBALDH1A1 | |
| SCHEMBL10331857 | 0.72 | NPSR1 (0.39) | TSHRNPSR1EDNRAEDNRBALDH1A1 | |
| SCHEMBL4780423 | 0.72 | ALDH1A1 (0.42) | TSHRNPSR1EDNRAEDNRBALDH1A1 | |
| SCHEMBL3588372 | 0.72 | ALDH1A1 (0.42) | TSHRNPSR1EDNRAEDNRBALDH1A1 | |
| SCHEMBL10355854 | 0.70 | EDNRA (0.50) | TSHRNPSR1EDNRAEDNRBALDH1A1 | |
| SCHEMBL11527593 | 0.70 | EDNRA (0.50) | TSHRNPSR1EDNRAEDNRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2011-11-03 | — | — | US | disclosed |
| EP-2344454-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | Queensland University Of Technology (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010037172-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269716-A1 | ANTIOXIDANT COMPOUNDS AND METHODS OF THEIR USE | NQO1, NFE2L2, GPX4 | TSHR 4251/4885NPSR1 2259/4885EDNRA 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.